Portfolio category: All

April 14, 2021 CTU admin

PUBLICATIONS The BRAIN TRIAL: a randomised, placebo controlled trial of a Bradykinin B2 receptor antagonist (Anatibant) in patients with traumatic brain injury Haleema Shakur, Peter Andrews, Toomas Asser, Laura Balica, Cristian Boeriu, Juan Diego Ciro Quintero, Yashbir Dewan, Patrick Druwe, Olivia Fletcher, Chris Frost, Bennie Hartzenberg, Jorge Mejia Mantilla, Francisco Murillo-Cabezas, Jan Pachl, Ramalingam R

WOMAN Pharmaco-TXA
June 12, 2020 CTU admin

Postpartum haemorrhage (PPH) is a leading cause of maternal mortality and morbidity. Tranexamic acid (TXA) significantly reduces death due to bleeding in women with PPH when given within three hours from birth. However, for many women, treatment is too late to prevent death from PPH. The aim of the WOMAN-PharmacoTXA trial is to assess the

May 1, 2019 CTU admin

Trauma-INTACT is a prospective, open-label, multicentre, pharmacokinetic study. Objective:  To assess the population pharmacokinetics of intramuscular TXA in trauma patients. Background:  The anti-fibrinolytic TXA has been licensed for over 30 years for use in the prevention and treatment of haemorrhage. More recently, large clinical trials have shown that TXA reduces death from bleeding after trauma and post-partum haemorrhage